Torrent Pharmaceuticals Ltd. · TORNTPHARM
Every Torrent Pharmaceuticals Ltd. result whose ten-session window has closed, judged against the last read made before it. Sector index NIFTY PHARMA. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
25results judged
3read right
0read wrong
3flat / no call
19unread
36%beat the market
-0.5%avg vs market, 10d
3.9%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| favourable | 4 | 2 | 0 | 2 | 100% | +2.9% | |
| neutral | 1 | 0 | 0 | 1 | — | +0.8% | |
| unfavourable | 1 | 1 | 0 | 0 | 100% | -3.0% | |
| unread | 19 | 0 | 0 | 0 | — | -1.1% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
25 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 30 Jul Q1FY27 | favourable | neutral | +3.7% | -0.8% | -1.0% | +10% | no figures |
|
› |
| 22 May Q4FY26 | neutral | neutral | -0.8% | -1.7% | +0.8% | +11% | no figures |
|
› |
| 13 Feb Q3FY26 | favourable | right | +4.4% | +7.1% | +9.5% | +6% | no figures |
|
› |
| 7 Nov Q2FY26 | favourable | right | +6.9% | +3.9% | +2.0% | -2% | no figures |
|
› |
| 28 Jul Q1FY26 | favourable | neutral | +3.0% | +0.1% | +0.9% | +11% | no figures |
|
› |
| 20 May Q4FY25 | unfavourable | right | -0.9% | -3.2% | -3.0% | +1% | no figures |
|
› |
| 24 Jan Q3FY25 | — | unread | +2.0% | -1.7% | -3.0% | -2% | no figures |
|
› |
| 25 Oct Q2FY25 | — | unread | -6.3% | -8.2% | -8.0% | -1% | no figures |
|
› |
| 23 Jul Q1FY25 | — | unread | -1.7% | +5.9% | +6.6% | +10% | no figures |
|
› |
| 24 May Q4FY24 | — | unread | +2.1% | +9.6% | +8.3% | +1% | no figures |
|
› |
| 2 Feb Q3FY24 | — | unread | +3.4% | +3.5% | +2.3% | +18% | no figures |
|
› |
| 25 Oct Q2FY24 | — | unread | +0.7% | +6.5% | +5.8% | -1% | no figures |
|
› |
| 7 Aug Q1FY24 | — | unread | +1.1% | -5.5% | -4.7% | +10% | no figures |
|
› |
| 30 May Q4FY23 | — | unread | +3.6% | +6.0% | +5.5% | +8% | no figures |
|
› |
| 25 Jan Q3FY23 | — | unread | -0.6% | -2.3% | -2.1% | -4% | no figures |
|
› |
| 21 Oct Q2FY23 | — | unread | +0.3% | +5.0% | +1.7% | +4% | no figures |
|
› |
| 29 Jul Q1FY23 | — | unread | -0.8% | +1.9% | -2.7% | +11% | no figures |
|
› |
| 25 May Q4FY22 | — | unread | +11.5% | +9.7% | +6.8% | -6% | no figures |
|
› |
| 25 Jan Q3FY22 | — | unread | -15.9% | -17.8% | -19.7% | +1% | no figures |
|
› |
| 27 Oct Q2FY22 | — | unread | -5.5% | -3.7% | -1.6% | -6% | no figures |
|
› |
| 27 Jul Q1FY22 | — | unread | +1.2% | -3.4% | -6.8% | +1% | no figures |
|
› |
| 18 May Q4FY21 | — | unread | -0.0% | +2.6% | -0.5% | +7% | no figures |
|
› |
| 8 Feb Q3FY21 | — | unread | -6.2% | -12.1% | -9.4% | — | no figures |
|
› |
| 26 Oct Q2FY21 | — | unread | -4.2% | -8.5% | -15.8% | -5% | no figures |
|
› |
| 30 Jul Q1FY21 | — | unread | +11.9% | +16.5% | +15.8% | -3% | no figures |
|
› |